Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 6Phase 1/2 4

Status

Completed 3Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4Neoplasm Metastasis 2

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × orteronel × Genitourinary × Clear all
NCT01084655 2019-07-30

Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

Takeda

Phase 1/2 Completed
38 enrolled 29 charts
Genitourinary

Prostatic Neoplasms

NCT01666314 2018-03-20

Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer

Takeda

Phase 1/2 Completed
137 enrolled 41 charts
Genitourinary

Prostatic Neoplasms

NCT00569153 2016-04-04

TAK-700

Millennium Pharmaceuticals, Inc.

Phase 1/2 Completed
123 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT02054793 2014-07-23

Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)

Johns Hopkins University

Phase 1/2 Withdrawn
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡